High serum macrophage inflammatory protein‑3α is associated with the early recurrence or metastasis of non‑small cell lung cancer following primary pulmonary resection
- Authors:
- Published online on: June 5, 2014 https://doi.org/10.3892/ol.2014.2229
- Pages: 948-952
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The present study sought to characterize the role of macrophage inflammatory protein‑3α (MIP‑3α) in non‑small cell lung cancer (NSCLC) patients with early recurrence or metastasis after primary pulmonary resection. Follow‑up examinations were conducted for 203 NSCLC patients with primary pulmonary resection for two years post‑operatively, and data was also collected for 20 healthy subjects. Serum MIP‑3α levels were determined prior to surgery and at post‑operative days (PODs) 30, 90 and 180, and the relevant clinical and operative variables were collected. Serum MIP‑3α was measured using a commercially available enzyme‑linked immunosorbent assay. There were no significant differences in age, gender and histological type among all groups (P>0.05). Serum MIP‑3α levels on POD 180 were significantly higher in the recurrence group than in the non‑recurrence group and healthy subjects (P=0.001). There was no significant difference in the serum MIP‑3α level at PODs 90 and 180 in the patients with or without adjuvant chemotherapy (P>0.05). The recurrence rate in the high serum MIP‑3α level group was 41.67%, much higher than the 23.53% observed in the low level group (P=0.006). The patients with high serum levels of MIP‑3α had a significantly shorter overall recurrence‑free time compared with those with low levels (P=0.004). Multivariate Cox's regression analyses showed that only serum MIP‑3α level was significant, with a hazard ratio of 1.061, a 95% confidence interval of 1.044‑1.078 and a P‑value of 0.001. The serum MIP‑3α level in the patients with liver and bone metastases were remarkably higher than those with recurrence at other sites. The high post‑operative serum MIP‑3α levels were associated with an increased risk of post‑operative early recurrence or metastasis in the lung cancer patients, specifically in those with bone or liver metastases.
